Protection against nephropathy in diabetes with atorvastatin
Phase of Trial: Phase III
Latest Information Update: 29 Jan 2015
At a glance
- Drugs Atorvastatin (Primary)
- Indications Diabetic nephropathies; Proteinuria
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms PANDA
- 19 Mar 2014 Accrual to date is 98% according to United Kingdom Clinical Research Network record.
- 17 Aug 2013 Accrual to date is 98% according to United Kingdom Clinical Research Network record.
- 15 Mar 2011 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History